Literature DB >> 22335591

Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.

Kristian Ikenberg1, Madeleine Pfaltz, Christiane Rakozy, Werner Kempf.   

Abstract

BACKGROUND: The mitotic rate was introduced as a major prognostic criterion for the staging of thin (≤1.0 mm) melanoma by the 2009 American Joint Committee on Cancer Staging and Classification (seventh edition). The detection of a single mitotic figure changes the tumor stage in thin melanoma. We sought to address the value of a dual staining to facilitate the determination of the mitotic rate and to assign the mitotic activity to melanocytes.
METHODS: The mitotic rate of melanoma cells was determined by dual phosphohistone-H3 (PHH3)/Melan-A immunohistochemistry. Results were compared with PHH3 staining alone and conventional hematoxylin and eosin (H&E)-stained slides of 15 melanomas with a tumor thickness <1.0 mm.
RESULTS: PHH3 staining clearly labeled cells in the mitotic cell cycle. The mitotic rate in the PHH3/Melan-A dual stain was equal to that derived by H&E staining. Time required for counting mitotic figures was significantly reduced.
CONCLUSIONS: The evaluation of mitotic rate with an immunohistochemical dual stain is faster (mean 63.0%) and more reliable than evaluation by routine H&E staining alone. Dual staining immunohistochemistry may be a useful additional tool to standardize the determination of mitotic rate and may be helpful in evaluation of challenging cases.
Copyright © 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22335591     DOI: 10.1111/j.1600-0560.2011.01858.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Authors:  Eleonora Duregon; Adele Cassenti; Alessandra Pittaro; Laura Ventura; Rebecca Senetta; Roberta Rudà; Paola Cassoni
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

2.  Dual Immunohistochemical Detection of Mitoses in Melanoma.

Authors:  Thomas M Soike; John C Maize; Jonathan S Ralston; Benjamin Hayes; Julie Swick
Journal:  Pathol Oncol Res       Date:  2017-02-12       Impact factor: 3.201

3.  Variability in mitotic figures in serial sections of thin melanomas.

Authors:  Stevan R Knezevich; Raymond L Barnhill; David E Elder; Michael W Piepkorn; Lisa M Reisch; Gaia Pocobelli; Patricia A Carney; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2014-09-16       Impact factor: 11.527

4.  Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Authors:  Christopher S Hale; Meng Qian; Michelle W Ma; Patrick Scanlon; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Yongzhao Shao; David Polsky; Iman Osman; Farbod Darvishian
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

5.  Immunohistochemical expression of hormone receptors in melanoma of pregnant women, nonpregnant women, and men.

Authors:  Jane H Zhou; Kevin B Kim; Jeffrey N Myers; Patricia S Fox; Jing Ning; Roland L Bassett; Hassan Hasanein; Victor G Prieto
Journal:  Am J Dermatopathol       Date:  2014-01       Impact factor: 1.533

Review 6.  Emerging clinical applications of selected biomarkers in melanoma.

Authors:  Michael T Tetzlaff; Carlos A Torres-Cabala; Penvadee Pattanaprichakul; Ronald P Rapini; Victor G Prieto; Jonathan L Curry
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-01-30

7.  Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis.

Authors:  Bih-Rong Wei; Charles H Halsey; Shelley B Hoover; Munish Puri; Howard H Yang; Brandon D Gallas; Maxwell P Lee; Weijie Chen; Amy C Durham; Jennifer E Dwyer; Melissa D Sánchez; Ryan P Traslavina; Chad Frank; Charles Bradley; Lawrence D McGill; D Glen Esplin; Paula A Schaffer; Sarah D Cramer; L Tiffany Lyle; Jessica Beck; Elizabeth Buza; Qi Gong; Stephen M Hewitt; R Mark Simpson
Journal:  Acad Pathol       Date:  2019-07-11

8.  H3K79me3T80ph is a Novel Histone Dual Modification and a Mitotic Indicator in Melanoma.

Authors:  Danielle R Martinez; Hunter W Richards; Qiushi Lin; Carlos A Torres-Cabala; Victor G Prieto; Jonathan L Curry; Estela E Medrano
Journal:  J Skin Cancer       Date:  2012-11-25

9.  Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.

Authors:  Patricia Switten Nielsen; Rikke Riber-Hansen; Henrik Schmidt; Torben Steiniche
Journal:  Diagn Pathol       Date:  2016-04-09       Impact factor: 2.644

Review 10.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.